So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

SINGAPORE—China is racing toward economic self-sufficiency by weaning itself off American technology. But it has made a ...

China has leaped from fast follower to global pioneer in drug discovery and development. We believe that Chinese companies ...

As geopolitical tensions prompt global pharmaceutical giants to pivot away from China, India's Contract Development and ...

For all the attention on U.S.-China AI competition, new studies point to China’s rapid rise in biotechnology, especially for ...

Indian CDMOs are strategically expanding through acquisitions in the US and Europe, driven by global pharma's nearshoring ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of ...

U.S. drug companies are increasingly licensing experimental medicines invented by Chinese firms. Recent deals could be worth ...

They worry tariffs, aimed at bringing drug production to the United States, could instead drive companies out of business ...

China’s National Medical Products Administration (NMPA) has conditionally approved Zymeworks’ zanidatamab for biliary tract ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed ...